HISUN(SH:600267) Mei Ri Jing Ji Xin Wen·2025-10-27 12:39Core Viewpoint - Haizheng Pharmaceutical announced a significant impairment loss totaling 64.44 million yuan, which will reduce the company's profit for the third quarter of 2025 by the same amount [1] Financial Performance - The company recognized a credit impairment loss of 1.4013 million yuan and an asset impairment loss of 63.0436 million yuan, leading to a total impairment of 64.4449 million yuan [1] - The impairment data is unaudited, and the final impact on the company's financials will be confirmed after the annual audit by the accounting firm [1] Revenue Composition - For the year 2024, Haizheng Pharmaceutical's revenue composition is as follows: - Pharmaceutical production: 58.46% - Drug sales: 39.29% - Other industries: 1.94% - Other businesses: 0.23% - CMO/CDMO/CRO business: 0.08% [1] Market Capitalization - As of the report, Haizheng Pharmaceutical has a market capitalization of 12.6 billion yuan [1]